<DOC>
	<DOC>NCT02833857</DOC>
	<brief_summary>This is a multicenter, open-label study to evaluate the safety and pharmacokinetics in pediatric subjects with secondary hyperparathyroidism receiving a single dose of AMG 416 at the end of hemodialysis.</brief_summary>
	<brief_title>A Single-dose Study in Paediatric Subjects Aged 2 to Less Than 18 Years With (sHPT) Receiving Haemodialysis</brief_title>
	<detailed_description>A Single-dose Study to Evaluate the Safety and Pharmacokinetics in Paediatric Subjects Aged 2 to less than 18 Years with (sHPT) Receiving Maintenance Haemodialysis</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<criteria>Subject's parent has provided informed consent and subject has provided assent Children Age 2 to less than 18 years Diagnosed with chronic kidney disease Diagnosed with secondary hyperparathyroidism receiving hemodialysis, Weighing at least 7 kg Laboratory results within specified range. Currently receiving treatment in another investigation device or drug study Subject has received cinacalcet therapy within 30 days History of prolongation QT interval Subject is taking any medications that are on the QT prolongation mediation list ECG measurements within specified range.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Secondary Hyperparathyroidism, chronic kidney disease, hemodialysis</keyword>
</DOC>